window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-108383172-1');

About Novigenix

Novigenix is an innovative Swiss molecular diagnostics company specializing in new generation blood tests for early detection of cancer. Colox®, our lead product is a proven molecular blood test designed to significantly reduce mortality from colorectal cancer through early detection and follow-up colonoscopy. Novigenix’s technology is based on a new generation of predictive gene expression profiles of circulating blood cells and concentration profile of tumor-derived protein markers in combination with state-of-the-art mathematical analytical models. Our predictive molecular signatures of biomarkers provide new and accurate solutions for the early detection of cancer.

Novigenix-Led Consortium Secures Eurostars Funding to Develop Multi-Omics Test for Colon Cancer Detection and Monitoring

By |2020-09-24T10:59:29+02:0021 January 2020|Communiqué de presse, News Novigenix|

Total amount up to €1 million awarded to consortium of leading cancer centers and innovative healthcare companies   LAUSANNE, SWITZERLAND - 07:00 CET, January 21, 2020 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced that a consortium, including Maastricht University (The Netherlands),

Novigenix Develops New NGS-based Immune Cell Type Specific RNA Signatures for Early Colon Cancer Detection

By |2019-12-11T17:10:45+02:0011 December 2019|Communiqué de presse, News Novigenix|

Immune cell type specific profiles correlate with traditional blood cell count method LAUSANNE, SWITZERLAND - 07:00 CET, December 11, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced the development of a new immune cell type specific Immuno-Transcriptomic signature for the detection

Novigenix and RadioMedix to Develop Neuroendocrine Cancer Precision Diagnostic Test

By |2019-10-14T09:58:08+02:0014 October 2019|Communiqué de presse, News Novigenix|

Test to measure response to radiopharmaceutical therapy LAUSANNE, SWITZERLAND - 07:00 CET, October 14, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced a collaboration agreement with RadioMedix Inc., a radiopharmaceutical company, to develop a precision diagnostic test based on Novigenix’s technology.

Novigenix Receives Reimbursement Coverage for Colox® in Switzerland

By |2019-10-09T09:09:47+02:009 October 2019|Communiqué de presse, Medical information, News Novigenix|

First liquid biopsy test reimbursed in Switzerland for colon cancer screening through private outpatient supplementary insurance product offered by Helsana LAUSANNE, SWITZERLAND - 07:00 CET, October  9, 2019  - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine. today announced that Helsana, the leading health insurance

Novigenix’s New Early Colon Cancer Detection Blood Test Demonstrates Positive Results

By |2019-09-30T10:26:27+02:0030 September 2019|Communiqué de presse, News Novigenix|

Data on test’s newly discovered blood signature presented at ESMO 2019 LAUSANNE, SWITZERLAND - 07:00 CET, September 30, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced promising data from a study of a new Immuno-Transcriptomic signature for early detection of colorectal

Novigenix and BioLizard Sign Collaboration Agreement for Development of NGS Based Diagnostic Algorithm

By |2019-09-19T10:08:45+02:0019 September 2019|Communiqué de presse, News Novigenix|

AI-based Diagnostic Algorithm for Colon Cancer test on NGS platform LAUSANNE, SWITZERLAND - 07:00 CET, September 19, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced a collaboration agreement with BioLizard, an innovative bioinformatics company that aims to solve the most challenging

Interview Jan Groen: Colorectal Cancer Blood Test Driven by Immuno-transcriptomics

By |2019-06-19T15:11:14+02:0019 June 2019|News Novigenix|

Source: TNMichele Wilson PhDScience Writer Immuno-transcriptomics is a field of study focused on analyzing gene expression modifications (mRNA signatures) induced by the immune response to various triggers, such as the onset of cancer. Through deep neural network and machine learning, Novigenix are generating mathematical models based on these mRNA signature analyses to predict the onset and progression

Novigenix Strengthens Board with Appointment of Francois Martelet, M.D. Non-Executive Director

By |2019-08-23T17:21:16+02:0018 June 2019|Communiqué de presse, News Novigenix|

LAUSANNE, SWITZERLAND - 07:00 CET, June 18, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes products for early cancer detection and precision medicine today announced the appointment of Francois Martelet, M.D. to its Board of Directors as a non-executive director. Dr. Martelet has over 25 years’ experience at both corporate and operational

Novigenix Developing NGS Version of Early Colorectal Cancer Detection Test

By |2019-08-23T17:23:56+02:0017 May 2019|Medical information, News Novigenix|

NEW YORK (GenomeWeb) – With a new CEO at its helm, Swiss molecular diagnostic firm Novigenix is developing a new version of Colox, its mRNA-based assay for early colorectal cancer detection that applies next-generation sequencing instead of RT-PCR. The firm began a study earlier this year to validate the assay, which measures cancer-specific transcriptomic

Novigenix Appoints Dr. Jan Groen as CEO to Lead Expansion to Multi-Product Cancer Diagnostic Platform Company

By |2019-05-13T13:36:00+02:0013 May 2019|Communiqué de presse, News Novigenix|

ImmunoTranscriptomic platform combines identification of immune cell mRNA signatures with AI for early cancer detection   LAUSANNE, SWITZERLAND - 07:00 CET, May 13, 2019 - Novigenix SA, a leading ImmunoTranscriptomics company that develops and commercializes products for early cancer detection and precision medicine today announced the appointment of Dr. Jan Groen to the position of Chief

Go to Top